Navigation Links
EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference on Alzheimer's Disease
Date:7/7/2009

WATERTOWN, Mass., July 7 /PRNewswire/ --

    WHAT:           EnVivo Pharmaceuticals to share results from its Ib/IIa
                    trial in Alzheimer's disease patients with its
                    nicotinic alpha-7 agonist EVP-6124.

    WHEN:           Wednesday, July 15, 2009.

    WHERE:          Alzheimer's Association 2009 International Conference
                    on Alzheimer's Disease (ICAD) in Vienna, Austria.

    WHO:            Dana Hilt, MD, senior vice president, clinical
                    development and chief medical officer, EnVivo
                    Pharmaceuticals.

    ADDITIONAL:     EVP-6124 is EnVivo's novel alpha-7 nicotinic
                    acetylcholine receptor agonist currently in development
                    for Alzheimer's disease and cognitive dysfunction
                    associated with schizophrenia.  In this trial, safety
                    and effects on cognition of EVP-6124 were tested in
                    Alzheimer's patients already on long term treatment
                    with acetylcholine esterase inhibitors.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Cognitive Disorders and Schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase 2a clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase 1 studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for Schizophrenia). For more information about EnVivo, visit www.envivopharma.com.


'/>"/>
SOURCE EnVivo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries
2. Startech Environmental Advises Shareholders to Take No Action in Response to Friendly LRL Tender Offer
3. Calling All Aspiring Filmmakers! The In The Know Short Film Competition Announces Call for Entries Women and Couples Encouraged to Enter TODAY, Share Their Fertility Stories and Inspire Others
4. Ronald McDonald House Charities(R) (RMHC(R)) and McDonalds(R) Seek Inspiring Stories Through New Share.Give.Hope. Campaign
5. Shared Race, Social Group Seem to Help People Relate
6. Connectyx Technologies Holdings Groups CEO Gives Shareholders a Summary of Events for First Half of 2009 and Announces Teleconference Call on July 9th to Discuss Future Strategy
7. Sally Field Shares Her Osteoporosis Story on EmpowHer
8. Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders
9. AlphaRx Shareholder Update
10. Seroquels First- and Second-Line Patient Share Has Grown Since Last Years Analysis of Prescribing Trends in Bipolar Disorder
11. Arcadia Resources Responds to Share Price Volatility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology: